The five public articles are kept as five separate entries in this section. The summaries stay close to the source material and link back to the original pages.
01
Osteoporosis management: international and Chinese guidelines
The article follows osteoporosis care across the full pathway: identifying people at high fracture risk, using bone-density testing and FRAX for risk stratification, and using fracture liaison services and long-term follow-up to reduce the risk of another fracture.
It emphasizes that osteoporosis and related fractures may have no obvious symptoms early on. The public material introduces the International Osteoporosis Foundation one-minute test, the Osteoporosis Self-assessment Tool for Asians (OSTA), DXA, and FRAX as ways to move from risk awareness to formal assessment.
The guideline comparison also connects lifestyle and bone-health education, risk classification, post-fracture coordination, and review after treatment. Osteoporosis is presented as a continuous process of screening, diagnosis, intervention, follow-up, and prevention of subsequent fractures.
02
Osteoporosis pharmacotherapy: from guidelines to practice
The article organizes treatment decisions around fracture risk, treatment goals, medication choice, safety, access, adherence, and follow-up. Treatment is considered for a prior vertebral or hip fragility fracture, a DXA T-score of -2.5 or lower, or low bone mass with additional fragility-fracture or FRAX risk.
Antiresorptive options include bisphosphonates, denosumab, raloxifene, and calcitonin; bone-forming therapy includes teriparatide; and romosozumab has both bone-forming and antiresorptive effects. The appropriate class depends on the person's risk profile and the balance of expected benefit and harm.
The source also stresses calcium and vitamin D assessment, correction of hypocalcaemia before antiresorptive treatment, monitoring during therapy, and cardiovascular-risk review when romosozumab is considered. This is educational material, not an individual prescription.
03
Myokines in muscle-bone crosstalk
The invited review treats osteoporosis as a systemic condition and describes muscle and bone as an interacting unit. Their relationship includes mechanical loading as well as biochemical communication through cytokines and peptides released by skeletal muscle, known as myokines.
Depending on the molecule and context, myokines can influence bone formation, bone resorption, or both. Muscle mass, exercise, aging, and inflammation may change myokine release, which helps explain why sarcopenia and osteoporosis can develop together.
The review traces the field from early work in 2003 to current evidence and discusses the potential for exercise, myokine pathways, and muscle-bone crosstalk to inform prevention and treatment. These are research directions rather than a stand-alone clinical recommendation.
04
IL-19 and aging-related bone metabolism research
The two reports examine IL-19, a member of the IL-10 cytokine family, in aging-related and inflammatory bone loss. In the aging model, IL-19 expression and secretion rise as bone loss develops; reduced Dnmt1 expression and promoter demethylation increase Atoh1 binding and help explain this change.
In an LPS-induced inflammatory bone-loss model, IL-19 levels increase in serum and bone marrow. Whole-body IL-19 deficiency protects against bone loss, while mechanistic work in bone-marrow stromal cells links IL-19 to Bcl6 and reduced osteoprotegerin (OPG), a pathway that may influence osteoclast activity.
Taken together, the findings present IL-19 as a possible link between aging, inflammation, and bone remodeling and as a candidate target for further osteoporosis research. The reports describe experimental mechanisms, not a currently approved IL-19 treatment.
05
Nature Reviews Endocrinology research highlight
The research highlight describes a possible role for liver-cell SIRT2 in aging-related liver-bone communication. It focuses on small extracellular vesicles (sEVs) released by liver cells, which can carry signals between the liver and bone-resorbing cells.
Among those signals, LRG1 is presented as a functional molecule in liver-cell-to-osteoclast communication. This places aging, liver metabolism, and bone remodeling in one biological pathway and provides a framework for studying how changes outside bone may contribute to osteoporosis.
The translational question is whether the sEV communication pathway or its cargo can be selectively modulated. The public highlight supports a research direction and potential target hypothesis; detailed experimental findings and clinical implications remain with the original paper.
